Last reviewed · How we verify

Atropine/Remifentanil

King Saud University · FDA-approved active Small molecule

This combination pairs atropine (a muscarinic antagonist) with remifentanil (an opioid agonist) to provide anticholinergic and analgesic/sedative effects during anesthesia.

This combination pairs atropine (a muscarinic antagonist) with remifentanil (an opioid agonist) to provide anticholinergic and analgesic/sedative effects during anesthesia. Used for Anesthesia induction and maintenance, Perioperative analgesia and sedation.

At a glance

Generic nameAtropine/Remifentanil
SponsorKing Saud University
Drug classAnticholinergic/Opioid combination
TargetMuscarinic acetylcholine receptor (atropine); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Atropine blocks muscarinic acetylcholine receptors to reduce secretions and prevent bradycardia, while remifentanil is a potent synthetic opioid that binds mu-opioid receptors to provide rapid-onset analgesia and sedation. Together, they are used as a balanced anesthetic combination, with atropine serving as an adjunct to mitigate opioid-induced side effects such as vagal stimulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: